|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Skin rash |
|
Central nervous system (CNS) stimulation |
|
visual disturbances |
|
Blood dyscrasias, specifically thrombocytopenia, leukopenia, and hemolytic anemia |
|
cholestatic jaundice |
|
CNS toxicity, specifically hallucinations, mood or other mental changes, increased intracranial pressure |
|
hypersensitivity |
|
metabolic acidosis |
|
paresthesia |
|
pseudomembranous colitis |
|
seizures |
|
skin rash, severe, including erythema multiforme |
|
Stevens-Johnson syndrome |
|
CNS toxicity |
|
gastrointestinal disturbance |
|
Photosensitivity |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Cerebral arteriosclerosis, severe |
|
>> Seizure disorders |
|
Glucose-6-phosphate dehydrogenase deficiency |
|
>> Hepatic function impairment |
|
>> Hypersensitivity to nalidixic acid or other quinolone derivatives |
|
Renal function impairment, severe |
|
|
ADULT DOSE:
|
|
Antibacterial-
Initial: Oral, 1 gram every six hours (four times a day) for one to two weeks.
Maintenance: Oral, 500 mg every six hours.
Note: Underdosing during the initial treatment may increase the likelihood of bacterial resistance . |
|
MAXIMUM ADULT DOSE:
|
|
4 grams daily.
Note: Doses up to 6 grams daily have been used in severe urinary tract infections, although side effects may be increased at high dosage.
|
|
PEDIATRIC DOSE:
|
|
Antibacterial-
Infants up to 3 months of age: Use is not recommended in infants up to 3 months of age since nalidixic acid causes arthropathy in immature animals.
Children 3 months to 12 years of age: Oral, 55 mg per kg of body weight per day in four equally divided doses for one to two weeks initially, followed by a maintenance dose of 33 mg per kg of body weight per day in four equally divided doses.
Children 12 years of age and over: See Usual adult and adolescent dose .
Note: Underdosing during the initial treatment may increase the likelihood of bacterial resistance . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|